Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569294 | 0.69 | SMN1; SMN2 (0.53) | PKMNPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL27193044 | 0.69 | RAB9A (0.77) | PKMRECQLNPC1RAB9AHTT | |
| SCHEMBL6406401 | 0.68 | KDR (0.51) | NPC1HTTMAPT | |
| SCHEMBL2868835 | 0.66 | P2RY1 (0.59) | PKMRECQLNPC1RAB9AHTT | |
| SCHEMBL17609477 | 0.65 | RAB9A (1.00) | PKMRECQLNPC1RAB9AHTT | |
| SCHEMBL9037821 | 0.64 | RAB9A (0.53) | PKMRECQLNPC1RAB9AHTT | |
| SCHEMBL11426554 | 0.63 | RAB9A (0.63) | PKMRECQLNPC1RAB9AHTT | |
| SCHEMBL3163583 | 0.62 | P2RY1 (0.74) | PKMNPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL1894047 | 0.62 | RAB9A (0.66) | PKMRECQLNPC1RAB9AHTT | |
| SCHEMBL30664572 | 0.62 | RAB9A (0.66) | PKMRECQLNPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059658-A1 | Pyridazinone | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059658-A1 | Pyridazinone | TYMP, TPMT, PDXK | PKM 634/4885RECQL 931/4885NPC1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.